Search research articles
Contact Us
Filters
Showing results (31-40 of 69) with videos related to
Page
of 7
Sort By:
Neoplasia (New York, N.Y.)
|
January 15, 2018
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
Lukas Krähenbühl, Simone M Goldinger, Joanna Mangana, et al.
The Journal of Investigative Dermatology
|
September 12, 2025
Three-Dimensional Total Body Photography Enables Automated Obesity-Related Comorbidity Screening in Dermatology
Alyssa Susanto, Sam Kahler, M A Nayomi Dulanjala Sewwandi, et al.
ESMO Open
|
August 11, 2018
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma
Reinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, et al.
The Oncologist
|
June 1, 2017
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma
Simon Bossart, Selina Thurneysen, Elisabeth Rushing, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 24, 2016
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Stefan Diem, Fabienne Keller, Reinhard Rüesch, et al.
Melanoma Research
|
January 19, 2017
Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
Silvia A Haueis, Pascale Kränzlin, Joanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2013
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study
Reinhard Dummer, Simone M Goldinger, Christian P Turtschi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
Simone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Melanoma Research
|
February 28, 2018
Sarcoid-like reactions in patients receiving modern melanoma treatment
Florentia Dimitriou, Anna L Frauchiger, Mirjana Urosevic-Maiwald, et al.
Plos One
|
May 7, 2025
Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab
Dagmar von Bubnoff, Christina Schmitt, Simone M Goldinger, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 69) with videos related to
Sort By:
Page
of 7
Neoplasia (New York, N.Y.)
|
January 15, 2018
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma
Lukas Krähenbühl, Simone M Goldinger, Joanna Mangana, et al.
The Journal of Investigative Dermatology
|
September 12, 2025
Three-Dimensional Total Body Photography Enables Automated Obesity-Related Comorbidity Screening in Dermatology
Alyssa Susanto, Sam Kahler, M A Nayomi Dulanjala Sewwandi, et al.
ESMO Open
|
August 11, 2018
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma
Reinhard Dummer, Olivier Michielin, Mirjam Chantal Nägeli, et al.
The Oncologist
|
June 1, 2017
Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma
Simon Bossart, Selina Thurneysen, Elisabeth Rushing, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 24, 2016
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Stefan Diem, Fabienne Keller, Reinhard Rüesch, et al.
Melanoma Research
|
January 19, 2017
Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
Silvia A Haueis, Pascale Kränzlin, Joanna Mangana, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 4, 2013
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study
Reinhard Dummer, Simone M Goldinger, Christian P Turtschi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
Simone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Melanoma Research
|
February 28, 2018
Sarcoid-like reactions in patients receiving modern melanoma treatment
Florentia Dimitriou, Anna L Frauchiger, Mirjana Urosevic-Maiwald, et al.
Plos One
|
May 7, 2025
Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab
Dagmar von Bubnoff, Christina Schmitt, Simone M Goldinger, et al.
Page
of 7